Tag: Cancer: Rectal
Adults Overdue for CRC Screen Rarely Receive Recommendation for Screening
Prevalence of reporting clinician recommendation was lower for non-Hispanic Asian, Black, Hispanic versus White adults
Few With CRC in Sub-Saharan Africa Receive Guideline-Concordant Care
Risk for death 3.49 times higher for those receiving no cancer treatment versus standard treatment or treatment with minor deviations
Cancer Screening Has Provided Significant Value to U.S. Population
Single-site cancer screening could save an additional 3.2 to 5.1 million life-years with perfect adherence
Gains in Colorectal Cancer Outcomes Slowing, Reversing
Since ~2010, declines in diagnoses and deaths among adults in their 50s and 60s have slowed
Findings of IDEA Collaboration Have Influenced Prescribing Patterns
Significant increasing trend seen for use of three months of adjuvant chemotherapy for resected stage III colon cancer
GI Symptoms Persist in Most Female Colorectal Cancer Survivors
Most common symptoms include bloating/gas, constipation, diarrhea
Time to Treatment Not Tied to Worse Outcomes in Young Colorectal Cancer Patients
Findings seen for both overall survival and cause-specific survival
People With Mental Disorders Less Likely to Complete CRC Screening
Furthermore, people with mental disorders have higher proportion of positive fecal immunochemical test results than the general population
ACP: Screening Average-Risk Adults for Colorectal Cancer Should Start at 50 Years
For asymptomatic average-risk adults, clinicians should consider not screening at age 45 to 49 years, according to ACP
Fruquintinib Provides Meaningful Benefit in Refractory Metastatic CRC
Significantly improved overall survival seen with fruiquintinib versus placebo, with favorable safety profile
